Intermediate filaments consist of fixve different classes: desmin.
v-imentin. glial filaments. neurofilaments and cytokeratins (CKs) (Bormer et al. 1994) . Cvtokeratins are structural elements of the cytoskeleton of both normal epithelia and their malignant counterparts. Twenty different CKs hax e been identified in human epithelial tissues and have been divided into two subfamilies. basic and acidic (CK 9-20) CKs. In the surface epithelium of the ovarx. CKs 7. 8. 18 and 19 are found (Moll et al. 1982 : Bodenmuller et al. 1994 (Moll et al. 1983 : Sundstrom et al. 1994 .
Although the biochemical pathwayvs by which soluble CK fragments are formed in malignant tissues and released into the circulation are not fullN understood. CK serum lex els have been widely reported to be useful indicators of tumour activity in several human malignancies. e.g. colorectal. prostate. breast. cervical. pancreatic and lung, cancer (Gion et al. 1994 : Kainz et al. 1994 : Plebani et al. 1993 ).
The serum tumour marker CYFRA 21-1 detects a fragment of CK 19 (Pujol et al. 1995) . Basically. CK 19 is expressed in all epithelia and epithelia-derixved tissues. but it has also been detected in other cell types. e.g. peripheral blood mononuclear cells Received 5 December 1997 Revised 16 March 1998 Accepted 24 March 1998 Correspondence to: C Tempfer. Department of Gynaecology and Obstetrics. Vienna University Medical School, A-1090 Vienna. Wahringer GCirtel 18-20. Austna (Novaes et al. 1997) . CK 19 has been shoxxn to be a marker of cytodifferentiation in the human fetal endocrine pancreas (Bouwens et al. 1997) . Elevated serum levels of CK 19 have been descnrbed in v-arious human malignancies. e.g. pancreatic. bladder and cervical cancer (Kainz et al. 1995 : Senga et al. 1996 : Grem et al. 1997 . CYFRA 2 1-1 has been shoxwn to be a clinicallv valuable prognostic and monitoringc marker in oesophageal cancer. head and neck cancer and in non-small-cell luncg cancer (NSCLC) (Plebamu et al. 1995 : Goumas et al. 1997 : Yamamoto et al. 1997 (Mobus et al. 1992 : Yanagibashi et al. 1997 . To the authors' knoxwledge. no data on serum levels of CYFRA 2 1-1 in ox arian cancer have been reported so far.
The aim of the present studv w-as to exvaluate xhether CYFRA 21-1. alone or in combination wxith CA 125. has a potential as a screening marker in epithelial oxarian cancer. Furthermore. we have compared preoperative serum lex els of CYFRA 2 1-1 and CA 125 in patients with benign ovarian cysts and epithelial oxvarian cancer. wxith recard to their value in the differential diarnosis of adnexal masses. Additionallv. w e hax-e inxestigated the prornostic potential of CYFRA 21-1 serum lexels evaluated before therapy. Serum lexels of cytokeratins are known to be elexated in several benign conditions. e.g. inflammatorv diseases (Ouhavoun et al. 1990 : Nakamura et al. 1997 ) and lixer disease (Sabbatini et al. 1988 (Hosmer et al. 1989 ) were used to analyse the influence of serum CYFRA 21-1 and CA 125 levels on the probability of malignancy. Using a logistic regression model. sensitivity and specificity were calculated for each possible threshold value of estimated probabilitv for malignancy. Based on these values. receiver operator characteristics (ROC) curxes (Campbell et al. 1996) were constructed ( Figure IA) . A logistic regression model was used to compare healthy xA omen and ovarian cancer patients with respect to their CYFRA 21-1 xalues.
Univariate and multivariate logistic regression analyses were used to compare patients with benign ovarian cysts and ovarian cancer patients with respect to their CYFRA 21-1 and CA 125 values. The ROC curves (Figure 1 B) show the influence of each of the two variables on the probability for malignancy. as well as the diagnostic power of their simultaneous consideration.
Comparison of serum levels between unpaired groups were made using the Mann-Whitney U-test. Sun ival probabilities were calculated by the product limit method of Kaplan and Meier.
Differences betseen groups in survixal curves were assessed ovanan cysts (n = 90) and ovarian cancer patients (n = 37) with respect to their CYFRA 21-1 (---), and CA 125 (-) serum levels, and with respect to the simultaneous consideration of both variables (----) British Joumal of Cancer (1998) In the present study. serum CYFRA 21-1 showxed a sensitivitx of 41 %7 and a specificity of 95% in ovarian cancer patients. The ROC It has to be stressed that all tumour marker results haxe to be interpreted wxith caution. Even CA 125. which is generallv established as a specific tumour marker for oxarian cancer. has been reported to be elexated in xvarious benign conditions as well as in other malignancies. e.g. endometriosis and endometrial cancer (Kramer et al. 1993 : Rose et al. 1994 . This is also true for cxtokeratins. which haxe been reported to be elevated in a wide xariety of human malignancies (Gion et al. 1994 : Sliutz et al. 1995 . This fact is based on the abundant expression of cytokeratins. wAhich are found in all epithelia and epithelia-derived tissues. Thus. cvtokeratins or cvtokeratin fragments are expressed in large quantities in all proliferating epithelial tissues. Diseases of the liver hax-e been reported to be associated with elexated serum lexels of cytokeratins (Sabbatini et al. 1988) . This is consistent w ith our findings of elex ated CYFRA 21-1 serum levels in patients wxith lix-er cirrhosis. When interpreting elex ated CYFRA 21-1 serum lexels. it has to be taken into account that CYFRA 21-1 is not a specific ovarian cancer tumour marker and that the coincidence of other bemnin diseases or malignancies may lead to elexated serum lexels and consequentlI to false-positix e test results. CK 19 has been described as an indicator of epithelial injuries in inflammatory diseases. e.g. parodontosis and chronic bronchitis (Ouhayoun et al. 1990 : Nakamura et al. 1997 . In the present study. CYFRA 21-1 was not increased in inflammatory bowel disease or pelxvic inflammatory disease. This indicates that inflammation per se is not sufficient to cause elevated CK levels.
In the present study. we found no correlation between CYFRA 21-1 serum lexvels and tumour staae. This finding supports the assumption that serum lexels of cytokeratins are not reflective of the tumour bulk but rather indicative of strongly proliferating, tumours (Bormer et al. 1994) .
Elevated serum levels of cvtokeratins have been shown to provide prognostic information in several malignancies (Kainz et al. 1994 : Carpelan-Holmstrom et al. 1996 . In our study. we found that increased CYFRA 21-1 serum levels before therapy are predictive of the patients' outcome in oxarian cancer. Patients x ith elexated CYFRA 21-1 serum lexels had a shortened oxerall and disease-free surxvival. Additional studies with an increased number of patients are justified to clarifx further the prognostic value of CYFRA 21-1 in ovarian cancer patients. In conclusion. our data indicate that CYFRA 21-1 is suitable neither as a screening marker nor as an additional tool for differential diagnosis of adnexal masses. Regarding benign diseases. patients with liver cirrhosis show extremely high cytokeratin levels. whereas inflammatory conditions are not invariably associated with elevated serum levels of CYFRA 21-1. In ovarian cancer patients. serum levels of CYFRA 21-1 are not associated with clinicopathological parameters. The most promising result of this study is the prognostic value of preoperative CYFRA 21-1 serum levels regarding overall and disease-free survival. Considering these results. CYFRA 21-1. while obviously not suitable for screening or differential diagnosis of adnexal masses. could be useful as an additional prognostic factor in ovarian cancer patients.
